Dalai SK, Khoruzhenko S, Drake CG, Jie CC, Sadegh-Nasseri S. Resolution of infection promotes a state of dormancy and long survival of CD4 memory T cells. Immunology and Cell Biology. 2011 Mar 1. [Epub ahead of print]. [ PubMed ] PDF

Hartman IZ, Kim A, Cotter RJ, Walter K, Dalai SK, Boronina T, Griffith W, Lanar DE, Schwenk R, Krzych U, Cole RN, Sadegh-Nasseri S. A reductionist cell-free major histocompatibility complex class II antigen processing system identifies immunodominant epitopes. Nature Medicine. 2010 Nov;16(11):1333-40. Epub 2010 Oct 31.
[ PubMed ] PDF

Sadegh-Nasseri S, Natarajan S, Chou CL, Hartman IZ, Narayan K, Kim A.
Conformational heterogeneity of MHC class II induced upon binding to different peptides is a key regulator in antigen presentation and epitope selection. Immunologic Research. 2010 Jul;47(1-3):56-64. Review.
[ PubMed ] PDF

Sadegh-Nasseri S, Dalai SK, Korb Ferris LC, Mirshahidi S.
Suboptimal engagement of the T-cell receptor by a variety of peptide-MHC ligands triggers T-cell anergy. Immunology. 2010 Jan;129(1):1-7. Epub 2009 Dec 2. Review. [ PubMed ] PDF

Narayan K, Su KW, Chou CL, Khoruzhenko S, Sadegh-Nasseri S. HLA-DM mediates peptide exchange by interacting transiently and repeatedly with HLA-DR1. Molecular Immunology. 2009 Sep;46(15):3157-62. Epub 2009 Jul 31. [ PubMed ] PDF

Narayan K, Perkins EM, Murphy GE, Dalai SK, Edidin M, Subramaniam S, Sadegh-Nasseri S. Staphylococcal enterotoxin A induces small clusters of HLA-DR1 on B cells. PLoS One. 2009 Jul 9;4(7). [ PubMed ] PDF
Dalai SK, Mirshahidi S, Morrot A, Zavala F, Sadegh-Nasseri S. Anergy in memory CD4+ T cells is induced by B cells. Journal of Immunology. 2008 Sep 1;181(5):3221-31. [ PubMed ] PDF

Sadegh-Nasseri S, Chen M, Narayan K, Bouvier M. The convergent roles of tapasin and HLA-DM in antigen presentation. Trends in Immunology. 2008 Mar; 29 (3): 141-7 . Epub 2008 Feb 7. [ PubMed ] PDF

Chou CL, Mirshahidi S, Su KW, Kim A, Narayan K, Khoruzhenko S, Xu M, Sadegh-Nasseri S. Short peptide sequences mimic HLA-DM functions. Molecular Immunology. 2008 Apr;45(7):1935-43. Epub 2007 Dec 3.
[ PubMed ] PDF

Narayan K, Chou CL, Kim A, Hartman IZ, Dalai S, Khoruzhenko S, Sadegh-Nasseri S. (2007) HLA-DM targets the hydrogen bond between the histidine at position beta81 and peptide to dissociate HLA-DR-peptide complexes. Nature Immunology. 2007 Jan;8(1):92-100. Epub 2006 Dec 3. [ PubMed ] PDF

Publication featured in JHU newsletter here (in the format for non-science readers) PDF

Mirshahidi, S. Ferris, L. C., Sadegh-Nasseri, S. (2004) The magnitude of TCR engagement is a critical predictor of T cell anergy or activation. Journal of. Immunology. 172: 5346-5355 [ PubMed ] PDF

Mirshahidi S., Huang CT, Sadegh-Nasseri S. (2001) Anergy in Peripheral Memory CD4+ T Cells Induced by Low Avidity Engagement of T Cell Receptor. Journal of Experimental Medicine 194: 719-732 [ PubMed ] PDF

Chou, C.-L., and S. Sadegh-Nasseri. (2000) HLA-DM Recognizes the Flexible Conformation of Major Histocompatibility Complex Class II. Journal of Experimental Medicine. 192:1697-1706 [ PubMed ] PDF

Sato AK, Zarutskie JA, Rushe MM, Lomakin A, Natarajan SK, Sadegh-Nasseri S, Benedek GB, Stern LJ. (2000) Determinants of the peptide-induced conformational change in the human class II major histocompatibility complex protein HLA-DR1. Journal of Biological Chemistry. 275(3):2165-73 [ PubMed ] PDF

Korb, L., S. Mirshahidi, K. Ramyar, A. Sadighi Akha & S. Sadegh-Nasseri. (1999) Induction of T cell anergy by low numbers of agonist ligands. Journal of Immunology. 162: 6401-6409 [ PubMed ] PDF

Natarajan, S. K., M. Assadi, & S. Sadegh-Nasseri. (1999) Stable peptide binding to MHC class II molecules is rapid and is determined by a receptive conformation shaped by prior association of low affinity peptides. Journal of Immunology. 162: 4030-4036 [ PubMed ] PDF

Natarajan SK, Stern LJ, Sadegh-Nasseri S. (1999) Sodium dodecyl sulfate stability of HLA-DR1 complexes correlates with burial of hydrophobic residues in pocket 1. Journal of Immunology. 162(6):3463-70 [ PubMed ] PDF

Zhu X, Bavari S, Ulrich R, Sadegh-Nasseri S, Ferrone S, McHugh L, Mage M. (1997) A recombinant single-chain human class II MHC molecule (HLA-DR1) as a covalently linked heterotrimer of alpha chain, beta chain, and antigenic peptide, with immunogenicity in vitro and reduced affinity for bacterial superantigens. European Journal of Immunology. 27(8):1933-41 [ PubMed ]
German RN, Castellino F, Han R, Reis e Sousa C, Romagnoli P, Sadegh-Nasseri S, Zhong GM. (1996) Processing and presentation of endocytically acquired protein antigens by MHC class II and class I molecules. Immunological Reviews. 151:5-30 [ PubMed ]
Park SJ, Sadegh-Nasseri S, Wiley DC. (1995) Invariant chain made in Escherichia coli has an exposed N-terminal segment that blocks antigen binding to HLA-DR1 and a trimeric C-terminal segment that binds empty HLA-DR1.
Proceedings of the National Academy of Sciences of the USA. 92(24):11289-93 [ PubMed ] PDF
Nauss JL, Reid RH, Sadegh-Nasseri S. (1995) Accuracy of a structural homology model for a class II histocompatibility protein, HLA-DR1: comparison to the crystal structure. Journal of Biomolecular Structure and Dynamics. 12(6):1213-33. [ PubMed ]
Sadegh-Nasseri, S., L.J. Stern, D. C. Wiley & RN Germain. (1994) MHC class II function preserved by low-affinity peptide interactions preceding stable binding. Nature 370: 647-650 [ PubMed ] PDF

Wu S, Yang Y, Sadegh-Nasseri S, Ashwell JD. (1993) Use of bispecific heteroconjugated antibodies (anti-T cell antigen receptor x anti-MHC class II) to study activation of T cells with a full length or truncated antigen receptor zeta-chain. Journal of Immunology. 150(6):2211-21 [ PubMed ] PDF

Boehncke WH, Takeshita T, Pendleton CD, Houghten RA, Sadegh-Nasseri S, Racioppi L, Berzofsky JA, Germain RN. (1993) The importance of dominant negative effects of amino acid side chain substitution in peptide-MHC molecule interactions and T cell recognition. Journal of Immunology. 150(2):331-41 [ PubMed ] PDF
Sadegh-Nasseri S, Germain RN. (1992) How MHC class II molecules work: peptide-dependent completion of protein folding. Immunology Today. 13(2):43-6 [ PubMed ]

Sadegh-Nasseri, S. and R. N. Germain. (1991) A role for peptide in determining MHC class II structure. Nature 353: 167-170 [ PubMed ] PDF

Sadegh-Nasseri S, McConnell HM. (1989) A kinetic intermediate in the reaction of an antigenic peptide and I-Ek. Nature.337(6204):274-6[ PubMed ] PDF

Sadegh-Nasseri S, Phipps RP. (1988) Immunogenic presentation of an immunoglobulin "tolerogen" requires interleukin 2. European Journal of Immunology. 18(3):417-23.[ PubMed ] PDF
Gammon G, Shastri N, Cogswell J, Wilbur S, Sadegh-Nasseri S, Krzych U, Miller A, Sercarz E. (1987) The choice of T-cell epitopes utilized on a protein antigen depends on multiple factors distant from, as well as at the determinant site. Immunologial Reviews. 98:53-73 [ PubMed ]
Sadegh-Nasseri S, Dessi V, Sercarz EE. Selective reversal of H-2-linked genetic unresponsiveness to lysozymes. II. Alteration in the T helper/T suppressor balance, owing to gene(s) linked to Ir-2, leads to responsiveness in BALB.B. (1986) European Journal of Immunology. 16(5):486-92 [ PubMed ]

Sadegh-Nasseri S, Kipp DE, Taylor BA, Miller A, Sercarz E. Selective reversal of H-2 linked genetic unresponsiveness to lysozymes. I. Non-H-2 gene(s) closely linked to the Ir-2 locus on chromosome 2 permit(s) an antilysozyme response in H-2b mice. (1984) Immunogenetics. 20(5):535-46 [ PubMed ]







Timeline of Immunology (source - Wikipedia)

2005 – Development of human papillomavirus vaccine (Ian Frazer)
2001 – Discovery of FOXP3 – the gene directing regulatory T cell development
1996-1998 – Identification of Toll-like receptors
1995 – Regulatory T cells (Shimon Sakaguchi)
1995 – First dendritic cell vaccine trial reported by Mukherji et al.
1994 – 'Danger' model of immunological tolerance (Polly Matzinger)
1992- Discovery of transitional B cells (David Allman & Michael Cancro)
1991 – Role of peptide for MHC Class II structure (Scheherazade Sadegh-Nasseri & Ronald N. Germain)
1990 – Gene therapy for SCID
1988 – Discovery of biochemical initiators of T-cell activation: CD4- and CD8-p56lck complexes (Christopher E. Rudd)
1986 – Th1 vs Th2 model of T helper cell function (Timothy Mosmann)
1986 – Hepatitis B vaccine produced by genetic engineering
1985-1987 – Identification of genes for the T cell receptor
1984 – The first single cell analysis of lymphocyte proliferation (Doreen Cantrell) and (Kendall A. Smith)
1983 – Discovery of the T cell antigen receptor TCR (Ellis Reinherz) (Philippa Marrack) and (John Kappler) (James Allison)
1983 – Discovery of HIV (Luc Montagnier)
1981 – Discovery of the IL-2 receptor IL2R (Kendall A. Smith)
1980-1983 – Discovery and characterization of the first interleukins, 1 and 2 IL-1 IL-2 (Kendall A. Smith)
1979 – Generation of the first monoclonal T cells (Kendall A. Smith)
1976 – Identification of somatic recombination of immunoglobulin genes (Susumu Tonegawa)
1975 – Generation of the first monoclonal antibodies (Georges Köhler) and (César Milstein)
1974 – T-cell restriction to major histocompatibility complex (Rolf Zinkernagel and (Peter C. Doherty)
1973 – Dendritic Cells first described by Ralph M. Steinman
1972 – Structure of the antibody molecule
1971 – Peter Perlmann and Eva Engvall at Stockholm University invented ELISA
1969 – The lymphocyte cytolysis Cr51 release assay (Theodore Brunner) and (Jean-Charles Cerottini)
1968 – Passenger leukocytes identified as significant immunogens in allograft rejection (William L. Elkins and Ronald D. Guttmann)
1967 – Identification of IgE as the reaginic antibody (Kimishige Ishizaka)
1965 – Secretory immunoglobulins
1965 – Discovery of the first lymphocyte mitogenic activity, "blastogenic factor" (Shinpei Kamakura) and (Louis Lowenstein) (J. Gordon) and (L.D. MacLean)
1965 – Discovery of "immune interferon" (gamma interferon) (E.F. Wheelock)
1964-1968 T and B cell cooperation in immune response
1963 – Development of the plaque assay for the enumeration of antibody-forming cells in vitro (Niels Jerne) (Albert Nordin)
1961-1962 Discovery of thymus involvement in cellular immunity (Jacques Miller)
1961- Demonstration that glucocorticoids inhibit PHA-induced lymphocyte proliferation (Peter Nowell)
1960 – Discovery of lymphocyte "blastogenic transformation" and proliferation in response to mitogenic lectins-phytohemagglutinin (PHA) (Peter Nowell)
1959–1962 – Discovery of antibody structure (independently elucidated by Gerald Edelman and Rodney Porter)
1959 – Discovery of lymphocyte circulation (James Gowans)
1958–1962 – Discovery of human leukocyte antigens (Jean Dausset and others)
1957 – Discovery of interferon by Alick Isaacs and Jean Lindenmann
1957 – Clonal selection theory (Frank Macfarlane Burnet)
1953 – immunological tolerance hypothesis
1953 – Graft-versus-host disease
1951 – vaccine against yellow fever
1949 – immunological tolerance hypothesis
1949 – growth of polio virus in tissue culture, neutralization with immune sera, and demonstration of attenuation of neurovirulence with repetitive passage (John Enders) and (Thomas Weller) and (Frederick Robbins)
1948 – antibody production in plasma B cells
1946 – identification of mouse MHC (H2) by George Snell and Peter A. Gorer
1945 – Coombs Test aka antiglobulin test (AGT)
1944 – hypothesis of allograft rejection
1942 – Anaphylaxis (Karl Landsteiner and Merill Chase)
1942 – Adjuvants (Jules Freund and Katherine McDermott)
1940 – Identification of the Rh antigens (Karl Landsteiner and Alexander Weiner)
1938 – Antigen-Antibody binding hypothesis (John Marrack)
1924 – Reticuloendothelial system
1921 – Cutaneous allergic reactions (Otto Prausnitz and Heinz Küstner)
1917 – hapten (Karl Landsteiner)
1911 – 2nd demonstration of filterable agent that caused tumors (Peyton Rous)
1909 – Paul Ehrlich proposes "immune surveillance" hypothesis of tumor recognition and eradication
1905 – "Serum sickness" allergy (Clemens von Pirquet and (Bela Schick)
1903 – Opsonization
1903 – Intermediate hypersensitivity, the "Arthus reaction" (Maurice Arthus)
1902 – Immediate hypersensitivity anaphylaxis (Paul Portier) and (Charles Richet)
1901 – blood groups (Karl Landsteiner)
1900 – Antibody formation theory (Paul Ehrlich)
1896 – An antibacterial, heat-labile serum component (complement) is described (Jules Bordet)
1894 – Bacteriolysis (Richard Pfeiffer)
1893 – Use of live bacteria and bacterial lysates to treat tumors-"Coley's Toxins" (William B. Coley)
1891 – Demonstration of cutaneous (delayed type) hypersensitivity (Robert Koch)
1890 – Demonstration of antibody activity against diphtheria and tetanus toxins. Beginning of humoral theory of immunity. (Emil von Behring) and (Kitasato Shibasaburō)
1888 – Identification of bacterial toxins (diphtheria bacillus) (Pierre Roux and Alexandre Yersin)
1888 – Bactericidal action of blood (George Nuttall)
1885 – Introduction of concept of a "therapeutic vaccination". First report of a live "attenuated" vaccine for rabies (Louis Pasteur).
1883 – 1905 – Cellular theory of immunity via phagocytosis by macrophages and microphages (polymorhonuclear leukocytes) (Elie Metchnikoff)
1880 – 1881 -Theory that bacterial virulence could be attenuated by culture in vitro and used as vaccines. Proposed that live attenuated microbes produced immunity by depleting host of vital trace nutrients. Used to make chicken cholera and anthrax "vaccines" (Louis Pasteur)
1878 – Confirmation and popularization of the germ theory of disease (Louis Pasteur)
1877 – Mast cells (Paul Ehrlich)
1876 – First demonstration that microbes can cause disease-anthrax (Robert Koch)
1867 – First aseptic practice in surgery using carbolic acid (Joseph Lister)
1862 – phagocytosis (Ernst Haeckel)
1857-1870 – Confirmation of the role of microbes in fermentation (Louis Pasteur)
1850 – Demonstration of the contagious nature of puerperal fever (childbed fever) (Ignaz Semmelweis)
1840 – First "modern" proposal of the germ theory of disease (Jakob Henle)
1838 – Confirmation of the role of yeast in fermentation of sugar to alcohol (Charles Cagniard-Latour)
1837 – First description of the role of microbes in putrefaction and fermentation (Theodore Schwann)
1798 – First demonstration of vaccination smallpox vaccination (Edward Jenner)
1718 – Lady Mary Wortley Montagu, the wife of the British ambassador to Constantinople, observed the positive effects of variolation on the native population and had the technique performed on her own children.